Literature DB >> 26143525

Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs.

Raffaella Di Giacopo1, Luciano Cianetti2, Viviana Caputo3, Ilaria La Torraca4, Fiorella Piemonte5, Andrea Ciolfi2, Simona Petrucci6, Claudio Carta2, Paolo Mariotti7, Vincenzo Leuzzi8, Enza Maria Valente9, Adele D'Amico5, Annarita Bentivoglio10, Enrico Bertini5, Marco Tartaglia2, Giuseppe Zampino4.   

Abstract

OBJECTIVE: This work investigated the molecular cause responsible for a late-onset parkinsonism-dystonia phenotype in three Italian siblings, and clinically characterize this condition.
METHODS: Extensive neurophysiological and neuroradiological exams were performed on the three sibs. Most frequent late-onset metabolic diseases were ruled out through laboratory and biochemical analyses. A whole exome sequencing (WES) approach was used to identify the molecular cause underlying this condition. RESULTS AND
CONCLUSIONS: Peculiar neurologic phenotype was characterized by dystonia-parkinsonism, cognitive impairment, gait ataxia and apraxia, pyramidal signs. WES analysis allowed the identification of a compound heterozygosity for two nucleotide substitutions (c.1340G>A, p.R447H; c.790C>T, p.Q264X) affecting the TPP1 gene in the three affected siblings. Biochemical analyses demonstrated abrogated TPP1 catalytic activity in primary skin fibroblasts, but revealed residual activity in leukocytes. Our findings document that late infantile neuronal ceroid lipofuscinosis (CLN2), which is caused by TPP1 gene mutations, should be considered in the differential diagnosis of autosomal recessive dystonia-parkinsonism syndromes. The availability of enzyme replacement therapy and other therapeutic approaches for ceroid lipofuscinoses emphasizes the value of reaching an early diagnosis in patients with atypical and milder presentation of these disorders.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autosomal recessive Parkinson–dystonia; Differential diagnoses of late infantile parkinsonism; Late infantile ceroid lipofuscinoses; Protracted CLN2 disease; TPP1 gene mutations; Whole exome sequencing

Mesh:

Substances:

Year:  2015        PMID: 26143525     DOI: 10.1016/j.jns.2015.05.021

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

Review 1.  Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features.

Authors:  Serena Galosi; Francesca Nardecchia; Vincenzo Leuzzi
Journal:  Mov Disord Clin Pract       Date:  2020-02-04

2.  A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.

Authors:  Vicki J Swier; Katherine A White; Tyler B Johnson; Jessica C Sieren; Hans J Johnson; Kevin Knoernschild; Xiaojun Wang; Frank A Rohret; Christopher S Rogers; David A Pearce; Jon J Brudvig; Jill M Weimer
Journal:  Neurotherapeutics       Date:  2022-09-13       Impact factor: 6.088

3.  Visual perception and macular integrity in non-classical CLN2 disease.

Authors:  Angela Schulz; Simon Dulz; Yevgeniya Atiskova; Jan Wildner; Eva Wibbeler; Miriam Nickel; Martin Stephan Spitzer; Christoph Schwering
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-02       Impact factor: 3.535

Review 4.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

5.  Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.

Authors:  J Schaefers; L J van der Giessen; C Klees; E H Jacobs; S Sieverdink; M H G Dremmen; J K H Spoor; A T van der Ploeg; J M P van den Hout; H H Huidekoper
Journal:  Orphanet J Rare Dis       Date:  2021-05-14       Impact factor: 4.123

6.  Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world.

Authors:  Charles M Lourenço; Andre Pessoa; Carmen C Mendes; Carolina Rivera-Nieto; Diane Vergara; Mónica Troncoso; Emily Gardner; Francisca Mallorens; Lina Tavera; Luis A Lizcano; Nora Atanacio; Norberto Guelbert; Norma Specola; Nury Mancilla; Carolina F M de Souza; Sara E Mole
Journal:  J Paediatr Child Health       Date:  2020-12-30       Impact factor: 1.954

7.  Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.

Authors:  Eva Wibbeler; Raymond Wang; Emily de Los Reyes; Nicola Specchio; Paul Gissen; Norberto Guelbert; Miriam Nickel; Christoph Schwering; Lenora Lehwald; Marina Trivisano; Laura Lee; Gianni Amato; Jessica Cohen-Pfeffer; Renée Shediac; Fernanda Leal-Pardinas; Angela Schulz
Journal:  J Child Neurol       Date:  2020-12-23       Impact factor: 1.987

8.  Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.

Authors:  Sara E Mole; Angela Schulz; Eben Badoe; Samuel F Berkovic; Emily C de Los Reyes; Simon Dulz; Paul Gissen; Norberto Guelbert; Charles M Lourenco; Heather L Mason; Jonathan W Mink; Noreen Murphy; Miriam Nickel; Joffre E Olaya; Maurizio Scarpa; Ingrid E Scheffer; Alessandro Simonati; Nicola Specchio; Ina Von Löbbecke; Raymond Y Wang; Ruth E Williams
Journal:  Orphanet J Rare Dis       Date:  2021-04-21       Impact factor: 4.123

9.  Autophagic vacuolar myopathy is a common feature of CLN3 disease.

Authors:  Josefine Radke; Randi Koll; Esther Gill; Lars Wiese; Angela Schulz; Alfried Kohlschütter; Markus Schuelke; Christian Hagel; Werner Stenzel; Hans H Goebel
Journal:  Ann Clin Transl Neurol       Date:  2018-10-14       Impact factor: 4.511

10.  Genetic landscape of pediatric movement disorders and management implications.

Authors:  Dawn Cordeiro; Garrett Bullivant; Komudi Siriwardena; Andrea Evans; Jeff Kobayashi; Ronald D Cohn; Saadet Mercimek-Andrews
Journal:  Neurol Genet       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.